We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there!
Drawing on our expertise in IHC and IHF assays, we have developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets.
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement.
Discover our latest study, titled Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Discover our latest article, published in Frontiers in Immunology.
The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5).
Here is our latest publication, titled Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Here is our latest publication, titled Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE).
Discover why there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets and how to achieve it.
Our data illustrated here through DC differentiation and mixed leukocyte reaction assays show that adenosine-mediated suppression results in the generation of phenotypically and functionally dysregulated DCs, and that this process is relieved by adenosine receptor antagonists.
Discover our latest publication, titled CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.
We have fully set up and characterized a syngeneic Lewis LLC1 mouse model for preclinical studies of novel therapeutic agents and anti-cancer strategies.